Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy
Nathalie Goemans, Eugenio Mercuri, Е. Д. Белоусова, et al.
Neuromuscular Disorders (2017) Vol. 28, Iss. 1, pp. 4-15
Open Access | Times Cited: 115

Showing 51-75 of 115 citing articles:

Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys
Utkarsh J. Dang, Michael Ziemba, Paula R. Clemens, et al.
Human Molecular Genetics (2020) Vol. 29, Iss. 15, pp. 2481-2495
Open Access | Times Cited: 27
Erythroid-Progenitor-Targeted Gene Therapy Using Bifunctional TFR1 Ligand-Peptides in Human Erythropoietic Protoporphyria
Arienne Mirmiran, Caroline Schmitt, Thibaud Lefèbvre, et al.
The American Journal of Human Genetics (2019) Vol. 104, Iss. 2, pp. 341-347
Open Access | Times Cited: 26
Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models
Roula Tsonaka, Mirko Signorelli, Ekrem Sabir, et al.
Human Molecular Genetics (2019) Vol. 29, Iss. 5, pp. 745-755
Open Access | Times Cited: 26
RNA-targeted drugs for neuromuscular diseases
Alessandra Ferlini, Aurélie Goyenvalle, Francesco Muntoni
Science (2020) Vol. 371, Iss. 6524, pp. 29-31
Open Access | Times Cited: 24
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
Theodora Markati, Liesbeth De Waele, Urlike Schara-Schmidt, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 23
Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies
Ilaria Andreana, Mathieu Repellin, Flavia Carton, et al.
Pharmaceutics (2021) Vol. 13, Iss. 2, pp. 278-278
Open Access | Times Cited: 21
Update of the Brazilian consensus recommendations on Duchenne muscular dystrophy
Alexandra Prufer de Queiroz Campos Araújo, Jonas Alex Morales Saute, Clarisse Pereira Dias Drumond Fortes, et al.
Arquivos de Neuro-Psiquiatria (2023) Vol. 81, Iss. 01, pp. 081-094
Open Access | Times Cited: 9
Multiomic characterization of disease progression in mice lacking dystrophin
Mirko Signorelli, Roula Tsonaka, Annemieke Aartsma‐Rus, et al.
PLoS ONE (2023) Vol. 18, Iss. 3, pp. e0283869-e0283869
Open Access | Times Cited: 9
RNA structure in alternative splicing regulation: from mechanism to therapy
Nengcheng Bao, Zhechao Wang, Jiayan Fu, et al.
Acta Biochimica et Biophysica Sinica (2024)
Open Access | Times Cited: 3
The Pharmacokinetics of 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy
Sieto Bosgra, Jessica A. Sipkens, S. de Kimpe, et al.
Nucleic Acid Therapeutics (2019) Vol. 29, Iss. 6, pp. 305-322
Closed Access | Times Cited: 24
Developments in reading frame restoring therapy approaches for Duchenne muscular dystrophy
Anne-Fleur Schneider, Annemieke Aartsma‐Rus
Expert Opinion on Biological Therapy (2020) Vol. 21, Iss. 3, pp. 343-359
Open Access | Times Cited: 21
Peripheral blood transcriptome profiling enables monitoring disease progression in dystrophic mice and patients
Mirko Signorelli, Mitra Ebrahimpoor, Olga Veth, et al.
EMBO Molecular Medicine (2021) Vol. 13, Iss. 4
Open Access | Times Cited: 19
Evaluation of Chemically Modified Nucleic Acid Analogues for Splice Switching Application
Bao T. Le, Suxiang Chen, Rakesh N. Veedu
ACS Omega (2023) Vol. 8, Iss. 51, pp. 48650-48661
Open Access | Times Cited: 8
Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy
Yuan Fang, Craig M. McDonald, Paula R. Clemens, et al.
Journal of Neuromuscular Diseases (2023) Vol. 10, Iss. 3, pp. 349-364
Open Access | Times Cited: 7
Muscle biopsies in clinical trials for Duchenne muscular dystrophy – Patients’ and caregivers’ perspective
Ingrid E.C. Verhaart, Johnson Alex, Sejal Thakrar, et al.
Neuromuscular Disorders (2019) Vol. 29, Iss. 8, pp. 576-584
Open Access | Times Cited: 21
Normative data on spontaneous stride velocity, stride length, and walking activity in a non-controlled environment
Margaux Poleur, Ana Ulinici, Aurore Daron, et al.
Orphanet Journal of Rare Diseases (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 16
Antisense therapies in neurological diseases
J.-B. Brunet de Courssou, Alexandra Dürr, David Adams, et al.
Brain (2021) Vol. 145, Iss. 3, pp. 816-831
Open Access | Times Cited: 16
Inhibiting Glycine Decarboxylase Suppresses Pyruvate-to-Lactate Metabolism in Lung Cancer Cells
Chern Chiuh Woo, Kavita Kaur, Wei Xin Chan, et al.
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 17
New and emerging pharmacotherapy for duchenne muscular dystrophy: a focus on synthetic therapeutics
Sharon M. Grages, Michael Bell, Daniel J. Berlau
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 7, pp. 841-851
Closed Access | Times Cited: 15
Renadirsen, a Novel 2′OMeRNA/ENA® Chimera Antisense Oligonucleotide, Induces Robust Exon 45 Skipping for Dystrophin In Vivo
Kentaro Ito, Hideo Takakusa, Masayo Kakuta, et al.
Current Issues in Molecular Biology (2021) Vol. 43, Iss. 3, pp. 1267-1281
Open Access | Times Cited: 13
Chemical Development of Therapeutic Oligonucleotides
Karin E. Lundin, Olof Gissberg, Smith Rjh, et al.
Methods in molecular biology (2019), pp. 3-16
Closed Access | Times Cited: 15
Current Genetic Survey and Potential Gene-Targeting Therapeutics for Neuromuscular Diseases
W. Chiu, Ya-Hsin Hsun, Kao-Jung Chang, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 24, pp. 9589-9589
Open Access | Times Cited: 14
Standardized Data Structures in Rare Diseases: CDISC User Guides for Duchenne Muscular Dystrophy and Huntington’s Disease
Ariana P. Mullin, Diane Corey, Emily C. Turner, et al.
Clinical and Translational Science (2020) Vol. 14, Iss. 1, pp. 214-221
Open Access | Times Cited: 13
A Dystrophin Exon-52 Deleted Miniature Pig Model of Duchenne Muscular Dystrophy and Evaluation of Exon Skipping
Yusuke Echigoya, Nhu Trieu, William Duddy, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 13065-13065
Open Access | Times Cited: 12
Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status
Craig M. McDonald, Jessica R. Marden, Perry B. Shieh, et al.
Journal of Comparative Effectiveness Research (2023)
Open Access | Times Cited: 5

Scroll to top